Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

What this study is about

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few clinical trials have examined if adjuvant ADT after surgery will prevent cancer recurrence. We aim to address this research oversight and test the hypothesis that for men at high risk of cancer recurrence, 1 year of ADT immediately after surgery will be safe and will significantly improve cancer outcomes.

Who can join (things the study team will check)

✅ You may be able to join if…

• undetectable PSA (<0.02 ng/ml) within 16 weeks post-operative;
• ≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)

🚫 You may not be able to join if…

• Unwilling to receive ADT;
• previously received ADT;
• lymph node metastases
• allergy to any form of ADT

Where this trial is running

• Nova Scotia Health, Halifax, Nova Scotia, Canada
• The Ottawa Hospital, Ottawa, Ontario, Canada
• Centre universitaire de santé McGill - McGill University Health Centre, Montreal, Quebec, Canada

Who to contact

Rodney Breau, Dr. · 613-737-8899 · rbreau@toh.on.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05169112.